Skip to content

To explore the mechanism of abnormal fine white matter structure and neurovascular coupling function in patients with chronic kidney disease accompanied by brain injury based on multimodal neuroimaging

To explore the mechanism of abnormal fine white matter structure and neurovascular coupling function in patients with chronic kidney disease accompanied by brain injury based on multimodal neuroimaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114549
Enrollment
Unknown
Registered
2025-12-15
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease with brain injury

Interventions

Chronic kidney disease is not accompanied by brain damage:N/A
Chronic kidney disease with brain injury:N/A
Healthy control group:N/A

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to No maximum

Inclusion criteria

Inclusion criteria: CKD Inclusion Criteria: 1. Age over 18 years, with a clear clinical diagnosis of CKD. 2. Laboratory tests completed within 3 days before the multimodal MRI examination; neuropsychological scale assessments conducted 1 hour before the multimodal MRI scan. 3. Right-handed. Healthy Control Group Inclusion Criteria: 1. No significant brain damage as assessed by neuropsychological scales. 2. Previously healthy, with no history of hypertension or diabetes. 3. Gender, age, and education level matched with the CKD group. 4. Right-handed.

Exclusion criteria

Exclusion criteria: 1.Current or previous history of mental or neurodegenerative diseases, such as schizophrenia, etc. 2. Current or past history of serious physical illness, such as craniocerebral trauma. 3. There is a history of alcohol abuse; 2.A history of drug or poison dependence or abuse. 4. Combined with autoimmune diseases, metabolic encephalopathy, thyroid or parathyroid dysfunction, etc. 5. Those with severe visual or auditory impairments or language disorders that cannot be evaluated on neuropsychological scales. 6. Those with contraindications to MRI.

Design outcomes

Primary

MeasureTime frame
Neuropsychological Scale Scoring;Creatinine;Uric acid;

Countries

China

Contacts

Public ContactPing Cheng

Ningbo Medical Centre Lihuili Hospital

chengp2136@163.com+86 574 87018807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026